|Dr. Jan G. J. van de Winkel Ph.D.||Co-Founder, Chief Exec. Officer and Pres||14.71M||N/A||56|
|Mr. David A. Eatwell||Chief Financial Officer and Exec. VP||7.04M||N/A||56|
|Ms. Jane Juel||Sr. Director of Operations & Resource Management||N/A||N/A||N/A|
|Mr. Peter Ros||Sr. Director of Fin. & Accounting and R&D Operations||N/A||N/A||N/A|
|Dr. Paul W. H. I. Parren Ph.D.||Sr. VP and Scientific Director||N/A||N/A||53|
Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer in Denmark and internationally. The company markets Arzerra, a human monoclonal antibody for the treatment of chronic lymphocytic leukemia (CCL); and DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM). Its products under development include Ofatumumab to treat CLL and follicular lymphoma; Ofatumumab (OMB157) for relapsing remitting multiple sclerosis; and Daratumumab to treat MM, Non-Hodgkin's lymphoma, and solid tumors, as well as natural killer/T-cell lymphoma, nasal type. The companys products under development also comprise Tisotumab vedotin for treating solid cancers; HuMax-AXL-ADC for solid cancers; Teprotumumab for the treatment of Graves' orbitopathy; AMG 714 for celiac disease; ADCT-301 (HuMax-TAC-ADC) to treat lymphoma and acute myeloid leukemia (AML) or acute lymphoblastic leukemia; JNJ-61186372 for non-small-cell lung cancer; and NJ-63709178 for the treatment of AML. In addition, it has approximately 20 active pre-clinical programs, including naked, bispecific, and immune effector function enhanced antibodies. The company was founded in 1999 and is based in Copenhagen, Denmark.
Genmab A/S’s ISS Governance QualityScore as of June 2, 2017 is 4. The pillar scores are Audit: 1; Board: 5; Shareholder Rights: 1; Compensation: 9.